CCCC
C4 Therapeutics, Inc. NASDAQ Listed Oct 2, 2020$3.50
+0.57%
vs $3.48
Mkt Cap $387.0M
52w Low $1.69
52.0% of range
52w High $5.17
50d MA $3.91
200d MA $2.86
P/E (TTM)
-2.9x
EV/EBITDA
—
P/B
1.1x
Debt/Equity
0.2x
ROE
-40.9%
P/FCF
-2.9x
RSI (14)
41.00
ATR (14)
$0.24
Beta
2.86
50d MA
$3.91
200d MA
$2.86
Avg Volume
3.8M
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
490 Arsenal Way · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | BMO | -0.26 | -0.20 | +23.1% | 3.17 | -2.8% | +0.0% | +16.1% | -1.4% | -1.9% | -9.6% | — |
| May 8, 2026 | BMO | — | — | — | 2.98 | +0.0% | -1.0% | +7.5% | +0.0% | +16.1% | -1.4% | — |
| May 7, 2026 | BMO | — | — | — | 2.93 | -0.7% | +1.7% | -1.0% | +7.5% | +0.0% | +16.1% | — |
| Feb 26, 2026 | BMO | -0.31 | -0.18 | +41.9% | 2.78 | +0.0% | -2.9% | +17.4% | -6.9% | +4.7% | -1.9% | — |
| Nov 6, 2025 | BMO | -0.47 | -0.44 | +6.4% | 2.38 | -1.3% | -1.7% | +0.0% | +6.0% | +0.0% | -1.2% | — |
| Aug 7, 2025 | BMO | -0.38 | -0.37 | +2.6% | 2.58 | +3.5% | -3.1% | -3.2% | -7.4% | +4.0% | +0.9% | — |
| May 7, 2025 | BMO | -0.48 | -0.37 | +22.9% | 1.50 | +2.0% | +2.7% | -4.5% | +7.5% | -5.1% | -8.7% | — |
| Feb 27, 2025 | BMO | -0.44 | -0.49 | -11.4% | 2.60 | -0.4% | +4.2% | -11.4% | -0.8% | +2.1% | -2.9% | — |
| Oct 31, 2024 | BMO | -0.40 | -0.35 | +12.5% | 5.33 | +4.9% | +5.3% | +15.0% | -5.6% | -2.0% | +1.2% | — |
| Aug 1, 2024 | BMO | -0.37 | -0.26 | +29.7% | 6.68 | -5.2% | -3.9% | -8.3% | +1.9% | -3.5% | +0.0% | — |
| May 8, 2024 | BMO | -0.41 | -0.41 | +0.0% | 6.45 | +1.6% | +5.4% | -9.4% | +0.2% | -2.8% | +1.8% | — |
| Feb 22, 2024 | BMO | -0.67 | -0.68 | -1.5% | 8.80 | +1.5% | +2.2% | +5.8% | +2.5% | +12.3% | +0.3% | — |
| Nov 1, 2023 | BMO | -0.65 | -0.55 | +15.4% | 1.32 | -2.3% | +6.1% | +11.4% | +16.0% | +3.3% | -1.1% | — |
| Aug 8, 2023 | BMO | -0.74 | -0.73 | +1.4% | 3.51 | +0.9% | -1.4% | -0.9% | -0.6% | -0.9% | +0.0% | — |
| May 4, 2023 | AMC | -0.78 | -0.71 | +9.0% | 3.23 | +5.3% | +1.9% | -1.8% | +2.8% | +1.8% | -0.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $2.78 | $2.78 | +0.0% | -2.9% | +17.4% | -6.9% | +4.7% | -1.9% |
| Feb 23 | Brookline Capital | Maintains | Buy → Buy | — | $2.16 | $2.15 | -0.5% | +6.5% | +3.9% | +15.9% | +0.4% | -2.9% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $2.26 | $2.30 | +1.8% | -9.3% | -2.0% | +1.0% | +3.0% | -3.3% |
| Sep 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $2.61 | $2.80 | +7.3% | -0.8% | -6.6% | -9.5% | +1.8% | +0.0% |
| Sep 23 | Barclays | Maintains | Overweight → Overweight | — | $2.61 | $2.80 | +7.3% | -0.8% | -6.6% | -9.5% | +1.8% | +0.0% |
| Sep 22 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.16 | $3.30 | +4.4% | -17.4% | -0.8% | -6.6% | -9.5% | +1.8% |
| Sep 15 | Stephens & Co. | Upgrade | Equal Weight → Overweight | — | $2.66 | $2.81 | +5.6% | +34.2% | -4.5% | -0.9% | -1.8% | -4.8% |
| Dec 19 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $3.66 | $4.00 | +9.3% | +5.2% | +2.6% | +2.8% | -4.7% | +3.4% |
| Aug 6 | BMO Capital | Maintains | Outperform → Outperform | — | $5.89 | $5.93 | +0.7% | +1.9% | -3.5% | +0.0% | -6.7% | +5.9% |
| May 9 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.45 | $6.55 | +1.6% | +5.4% | -9.4% | +0.2% | -2.8% | +1.8% |
| May 9 | Stifel | Maintains | Buy → Buy | — | $6.45 | $6.55 | +1.6% | +5.4% | -9.4% | +0.2% | -2.8% | +1.8% |
| Feb 26 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.99 | $9.00 | +0.1% | +5.8% | +2.5% | +12.3% | +0.3% | +0.1% |
| Feb 23 | Stifel | Maintains | Buy → Buy | — | $8.80 | $8.93 | +1.5% | +2.2% | +5.8% | +2.5% | +12.3% | +0.3% |
| Jan 29 | JP Morgan | Upgrade | Underweight → Neutral | — | $5.47 | $5.60 | +2.4% | +15.7% | -5.1% | +2.8% | -6.5% | -7.1% |
| Dec 13 | Stifel | Upgrade | Hold → Buy | — | $2.34 | $3.18 | +35.9% | +135.5% | -9.1% | -1.2% | -7.3% | -1.1% |
| Nov 6 | Morgan Stanley | Upgrade | Underweight → Equal Weight | — | $1.56 | $1.53 | -1.9% | +16.0% | +3.3% | -1.1% | -4.9% | -2.3% |
| Nov 3 | BMO Capital | Maintains | Outperform → Outperform | — | $1.40 | $1.42 | +1.4% | +11.4% | +16.0% | +3.3% | -1.1% | -4.9% |
| Nov 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.29 | -2.3% | +6.1% | +11.4% | +16.0% | +3.3% | -1.1% |
| Oct 9 | BofA Securities | Maintains | Neutral → Neutral | — | $1.71 | $1.73 | +1.2% | -5.3% | +16.7% | +0.5% | -3.2% | +8.2% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.51 | $3.54 | +0.9% | -1.4% | -0.9% | -0.6% | -0.9% | +0.0% |
| May 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $3.08 | $3.19 | +3.6% | +8.8% | +1.2% | -0.9% | +0.9% | +0.9% |
| May 12 | Morgan Stanley | Maintains | Underweight → Underweight | — | $3.37 | $3.37 | +0.0% | -3.3% | +2.5% | -7.2% | +1.3% | +1.3% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.29 | $3.32 | +0.9% | -1.8% | +2.8% | +1.8% | -0.3% | -3.3% |
| Mar 28 | BofA Securities | Maintains | Neutral → Neutral | — | $3.46 | $3.42 | -1.2% | -3.8% | +2.1% | -8.8% | +1.3% | +1.9% |
| Feb 27 | Morgan Stanley | Maintains | Underweight → Underweight | — | $5.33 | $5.36 | +0.6% | +0.2% | -1.3% | -4.2% | +0.4% | +1.6% |
| Feb 24 | JP Morgan | Downgrade | Neutral → Underweight | — | $6.02 | $5.34 | -11.3% | -11.5% | +0.2% | -1.3% | -4.2% | +0.4% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.02 | $5.34 | -11.3% | -11.5% | +0.2% | -1.3% | -4.2% | +0.4% |
| Jan 3 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $5.90 | $5.92 | +0.3% | +8.1% | +4.1% | -2.0% | +3.2% | +6.4% |
| Nov 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $8.86 | $8.89 | +0.3% | +2.5% | -14.1% | +12.7% | +2.8% | +0.8% |
| Nov 4 | JP Morgan | Downgrade | Overweight → Neutral | — | $9.90 | $9.31 | -6.0% | -10.0% | -0.6% | +2.5% | -14.1% | +12.7% |
| Oct 11 | Morgan Stanley | Maintains | Underweight → Underweight | — | $7.73 | $7.31 | -5.4% | -1.9% | +1.8% | +7.1% | -3.7% | +7.8% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.43 | $8.18 | -3.0% | -8.1% | -4.5% | -13.1% | +4.8% | +6.1% |
| Apr 28 | Credit Suisse | Maintains | Underperform → Underperform | — | $8.85 | $8.58 | -3.1% | +0.3% | -3.5% | +9.3% | -3.7% | +1.7% |
| Apr 18 | UBS | Maintains | Buy → Buy | — | $8.95 | $8.86 | -1.0% | +1.8% | +3.5% | -4.5% | -2.0% | +3.9% |
| Apr 11 | BMO Capital | Maintains | Outperform → Outperform | — | $11.32 | $10.19 | -10.0% | -29.2% | +9.4% | +6.7% | -4.3% | +1.8% |
| Mar 10 | JP Morgan | Maintains | Overweight → Overweight | — | $24.21 | $25.04 | +3.4% | -0.6% | -2.9% | -9.0% | +1.1% | +5.3% |
| Feb 10 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $24.51 | $23.57 | -3.8% | -3.0% | -0.5% | -3.9% | +5.2% | -2.6% |
| Nov 23 | BofA Securities | Maintains | Buy → Buy | — | $37.04 | $38.83 | +4.8% | +3.2% | -1.0% | -3.1% | -1.9% | +3.3% |
| Oct 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $41.58 | $41.94 | +0.9% | +6.4% | -0.8% | -2.2% | +3.5% | -3.6% |
| Sep 30 | Stifel | Maintains | Hold → Hold | — | $47.97 | $46.61 | -2.8% | -6.9% | +2.9% | -2.1% | -0.7% | +0.1% |
| Jun 24 | Brookline Capital | Maintains | Buy → Buy | — | $37.76 | $38.47 | +1.9% | -1.3% | +1.2% | -1.6% | -0.1% | +2.0% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.15 | $40.00 | +4.8% | +2.3% | +6.2% | -2.2% | +3.6% | +0.0% |
| Mar 31 | BMO Capital | Maintains | Outperform → Outperform | — | $32.90 | $33.00 | +0.3% | +12.4% | +4.4% | -2.9% | -0.1% | -3.5% |
| Oct 27 | BMO Capital | Maintains | Outperform → Outperform | — | $26.23 | $27.06 | +3.2% | -2.0% | -2.5% | +0.1% | -1.4% | -0.0% |
No insider trades available.
8-K
C4 Therapeutics, Inc. -- 8-K Filing
C4 Therapeutics appointed an independent registered public accounting firm to audit its fiscal 2026 financial statements, a routine administrative disclosure.
Jun 24
8-K · 7.01
! Medium
C4 Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jun 11
8-K · 2.02
!! High
C4 Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
CCCC amended its bylaws regarding officer duties and responsibilities, likely clarifying governance procedures; investors should monitor if this signals leadership changes or shifts in corporate structure affecting decision-making authority.
Apr 10
8-K · 1.01
!! High
Unknown — 8-K 1.01: License Agreement
CCCC secured a major pharmaceutical partnership with industry giant Roche, potentially validating its pipeline and providing near-term revenue through upfront payments and milestone fees.
Apr 9
8-K
C4 Therapeutics, Inc. -- 8-K Filing
C4 Therapeutics extended its cash runway past key milestones while advancing its lead drug cemsidomide through a differentiated regulatory pathway, demonstrating best-in-class potential in targeted protein degradation.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 17,963,324 | $34M | Added | Dec 2025 |
| 2 | Vanguard Capital Management Llc | 3,861,852 | $10M | New | Mar 2026 |
| 3 | Soleus Capital Management, L.p. | 3,803,942 | $10M | — | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 3,035,634 | $8M | Added | Mar 2026 |
| 5 | Jpmorgan Chase & Co | 3,223,054 | $8M | Added | Mar 2026 |
| 6 | Citadel Advisors Llc | 2,511,015 | $7M | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 2,461,815 | $6M | Added | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 2,359,241 | $6M | Added | Mar 2026 |
| 9 | Acadian Asset Management Llc | 1,890,914 | $5M | Added | Mar 2026 |
| 10 | Silverarc Capital Management, Llc | 1,994,224 | $4M | Added | Dec 2025 |
| 11 | Millennium Management | 1,393,342 | $4M | Added | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 1,286,840 | $3M | Reduced | Mar 2026 |
| 13 | D.e. Shaw & Co | 1,060,331 | $3M | Added | Mar 2026 |
| 14 | Wells Fargo & Company/mn | 867,911 | $2M | New | Mar 2026 |
| 15 | Qube Research & Technologies Ltd | 752,114 | $2M | Added | Mar 2026 |
| 16 | Jane Street Group, Llc | 874,794 | $2M | Added | Dec 2025 |
| 17 | Stempoint Capital Lp | 453,236 | $1M | New | Mar 2026 |
| 18 | Platinum Investment Management Ltd | 384,766 | $1M | New | Mar 2026 |
| 19 | Barclays Plc | 317,877 | $836K | Added | Mar 2026 |
| 20 | Fmr Llc | 272,368 | $716K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$387.0M
Enterprise Value
$41.6M
P/E (TTM)
-2.94x
Forward P/E
—
PEG Ratio
0.09x
P/B
1.13x
P/S
8.32x
P/FCF
-2.92x
EV/EBITDA
—
Shares Out
82.9M
Financials (TTM)
Revenue
$34.9M
Net Income
-$103.8M
EBITDA
-$100.4M
Free Cash Flow
-$99.3M
Op Cash Flow
-$98.7M
EPS Basic
$-1.27
EPS Diluted
$-1.19
EPS Forward
$-1.09
Gross Margin
94.8%
Op Margin
-326.6%
Net Margin
-297.8%
Balance Sheet
Total Assets
$359.1M
Total Liab.
$102.5M
Total Equity
$256.6M
Cash
$248.5M
LT Debt
$0
Book Value/Sh
$3.10
Debt/Equity
0.23x
Current Ratio
7.81
Quick Ratio
7.81
Returns & Growth
ROE
-40.9%
ROA
-29.2%
ROIC
-31.4%
Rev Growth YoY
+1.0%
EPS Growth YoY
+16.4%
Price Returns
2W
-2.2%
1M
-15.5%
3M
+15.1%
6M
+85.2%
12M
+66.7%
Technicals
52W High
$5.17
52W Low
$1.69
50d MA
$3.91
200d MA
$2.86
RSI (14)
41.00
ATR (14)
$0.24
Beta
2.86
Avg Volume
3.8M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 25, 2026 12:15am
· Source: financialmodelingprep.com